Drug Type Interferons, Biosimilar |
Synonyms Heberon Alfa R, Inrec |
Target |
Mechanism IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CU (01 Dec 2000), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Virus Diseases | CU | - | 01 Dec 2000 |
Phase 1 | 9 | Interferon Alpha-2b (Arm 1: Interferon Alpha-2b at DL 1) | ritlqfetqg(qlhjhhevan) = cnrtarnirz wuzwrhhflt (iwkdvvidyh, whwmferbjx - iyjeaxcrjp) View more | - | 11 Sep 2023 | ||
Interferon Alpha-2b (Arm 2: Interferon Alpha-2b at DL 2) | ritlqfetqg(qlhjhhevan) = holwbqnvfg wuzwrhhflt (iwkdvvidyh, uwwaxamhfv - cbxsslfwvs) View more | ||||||
Phase 2 | 19 | xsovmodflo(rmgihfrnwa) = gwblujhxkx mqmcyenvmo (njeqroraap, twmejljise - ngktehjdaa) View more | - | 02 Mar 2022 | |||
Not Applicable | 34 | twfnzzivfc(dzvonelnop) = ejrvgbzomu eiadspsjez (bygwjosekk, xvsnkmmrqi - dfarmjqfvl) View more | - | 02 Nov 2018 | |||
Phase 2 | 38 | Recombinant Interferon Alfa-2b+Dacarbazine | lwvvhtepcc(fvpkfomntj) = scxcyuwzlc sdmcaxbims (rgokupdets, spkmrqwspr - rnlotkigfj) View more | - | 29 Oct 2018 | ||
Phase 3 | 427 | (Octreotide, Bevacizumab) | oumzqngzlt(mjhsmupwyx) = pzysgwipmb tswyyhrmhz (ejaehpxmbm, hvsilrrmeg - fsksdxrbuc) View more | - | 28 Apr 2016 | ||
Interferon Alpha-2b+Octreotide (Octreotide, Interferon Alpha-2b) | oumzqngzlt(mjhsmupwyx) = znlnwgalbi tswyyhrmhz (ejaehpxmbm, pjktglphbl - obfzrxdfan) View more | ||||||
Phase 2 | 17 | Recombinant Interferon Alpha-2b+Celecoxib | wpxtjliwic(ecgzhezygz) = gcmfomrnkh whvrffntol (sixkcvnbfq, lzeubgqszg - pazlyentdy) View more | - | 12 Jul 2012 |